A Phase 3 interventional study of Diclofenac sodium gel 1% and Placebo in Muscle Soreness, sponsored by Novartis. Completed at 1 site in United States. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2016-04-05.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Myalgia with a site in United States — 12 open to participants now, 14 under way, none of them phase 3. Myalgia · United States.
Among the 86 studies in Myalgia with a site in United States, this one is the 16th largest by enrollment of the 77 interventional ones that give a count, is one of 4 that started in 2014, is one of 8 in phase 3, and was the 27th registered.
256 studies on the registry are indexed under Myalgia; 45 are open to participants now.
Browse Myalgia studies →12 of the 86 studies in Myalgia with a site in United States are open now. Recruiting first, the newest first:
Applied Science & Performance Institute · Sites in United States
Ages 20–55 · Men only · Healthy volunteers
Sam Houston State University · Sites in United States
Ages 18–60 · Healthy volunteers
Sam Houston State University · Sites in United States
Ages 18–60 · Healthy volunteers
University of Minnesota · Sites in United States
Ages 18–30 · Healthy volunteers
ESM Technologies, LLC · Sites in United States
Ages 18–40 · Men only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Myalgia studies recruiting now, 6 (23%) set no upper age limit and 19 (73%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 11 · Phase 4 7
First in 2002; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 44 across 216 interventional studies indexed under Myalgia.
Median enrollment 40 across the 77 interventional studies, 250 across the 9 observational. Of the 66 that completed or were terminated, 17 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 86 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Novartis has 1 study filed under Myalgia — fewer than ten, so there is no comparison to draw.
5 of the studies in Myalgia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07822048Sam Houston State UniversityEffects of Beef-Forward Ready-to-Eat Meals on Recovery Following Simulated Fire Suppression Activities | 2026-11-30 |
| NCT07819565Sam Houston State UniversityEffects of Pork Protein on Recovery Following Simulated Fireground Activity | 2026-11-30 |
| NCT07219498University of MinnesotaEffects of a 5-Week Probiotic Supplementation Intervention on Markers of Delayed Onset Muscle Soreness | 2026-12-31 |
| NCT07756658Applied Science & Performance InstituteThe Effects of Tyrosol and Creatine on Exercise Performance and Cognition in Healthy Adults | 2027-01-17 |
| NCT04128670Indiana UniversityEffects of Kinesio Tape on Delayed Onset Muscle Soreness | 2027-05-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 86 studies in Myalgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the analgesic efficacy of DSG 1% compared to placebo in the reduction of the pain associated with DOMS
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
diclofenac sodium gel 1% applied four times daily
Drug: Diclofenac sodium gel 1% · Drug: Placebo
Placebo gel applied four times daily
Drug: Diclofenac sodium gel 1% · Drug: Placebo
Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW.
The primary efficacy outcome was the time-weighted SPID 24 (POW). Sum of pain intensity differences over 24 hours after initiating treatment (SPID 24) for the modified ITT population. SPID 24 derived from Pain on Walking (POW) scores assessed over 24 hours on a 0 (No pain) - 10 (Pain as bad as you can imagine) Numerical Rating Scale. SPID 24 was computed using the trapezoidal rule, i.e. Σ \[T(i) - T(i-1)\] x \[((PID)(i-1) + PID(i))/2\] in an obvious notation, where T(i) is nominal time and PID(i), the pain intensity difference at Time i, is the baseline pain intensity (PI) score - PI score at Time i.
Time frame: 24 hours
Sum of Pain Intensity Differences Over 48 Hours After Initiating Treatment (SPID 48), Derived From POW.
Sum of pain intensity differences over 48 hours after initiating treatment (SPID 48) (POW) was a secondary outcome. Sum of pain intensity differences over 48 hours after initiating treatment (SPID 48) for the modified ITT population. SPID 48 derived from Pain on Walking (POW) scores assessed over 48 hours on a 0 (No pain) - 10 (Pain as bad as you can imagine) Numerical Rating Scale. SPID 48 was computed using the trapezoidal rule, i.e. Σ \[T(i) - T(i-1)\] x \[((PID)(i-1) + PID(i))/2\] in an obvious notation, where T(i) is nominal time and PID(i), the pain intensity difference at Time i, is the baseline pain intensity (PI) score - PI score at Time i.
Time frame: 48 hours
Study Start 7 Oct 2014 and End 24 dec 2014
| Milestone | Diclofenac Sodium Gel 1% and Placebo Gel |
|---|---|
| Started | 102 |
| Completed | 98 |
| Not completed | 4 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Unable or unwilling to cooperate with st | 1 |
| Withdrew: Lost to follow-up | 1 |
The primary efficacy outcome was the time-weighted SPID 24 (POW). Sum of pain intensity differences over 24 hours after initiating treatment (SPID 24) for the modified ITT population. SPID 24 derived from Pain on Walking (POW) scores assessed over 24 hours on a 0 (No pain) - 10 (Pain as bad as you can imagine) Numerical Rating Scale. SPID 24 was computed using the trapezoidal rule, i.e. Σ \[T(i) - T(i-1)\] x \[((PID)(i-1) + PID(i))/2\] in an obvious notation, where T(i) is nominal time and PID(i), the pain intensity difference at Time i, is the baseline pain intensity (PI) score - PI score at Time i.
| units on a scale (NRS) | Diclofenac Sodium Gel 1% | Placebo |
|---|---|---|
| Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW. | 50.15 ± 35.95 | 54.83 ± 37.04 |
Sum of pain intensity differences over 48 hours after initiating treatment (SPID 48) (POW) was a secondary outcome. Sum of pain intensity differences over 48 hours after initiating treatment (SPID 48) for the modified ITT population. SPID 48 derived from Pain on Walking (POW) scores assessed over 48 hours on a 0 (No pain) - 10 (Pain as bad as you can imagine) Numerical Rating Scale. SPID 48 was computed using the trapezoidal rule, i.e. Σ \[T(i) - T(i-1)\] x \[((PID)(i-1) + PID(i))/2\] in an obvious notation, where T(i) is nominal time and PID(i), the pain intensity difference at Time i, is the baseline pain intensity (PI) score - PI score at Time i.
| units on a scale (NRS) | Diclofenac Sodium Gel 1% | Placebo |
|---|---|---|
| Sum of Pain Intensity Differences Over 48 Hours After Initiating Treatment (SPID 48), Derived From POW. | 151.8 ± 81.9 | 160.84 ± 83.15 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Diclofenac Sodium Gel 1% | — | 0/102 (0%) | 0/102 (0%) |
ITT population: All randomized subjects who received at least one dose of the study drug on both legs = 102 Modified ITT population: Excludes the first 16 subjects who were systematically underdosed =86 Safety population: All randomized subjects who received at least one dose of study drug on either leg =102
| Age, Continuous(years) | Diclofenac Sodium Gel 1% |
|---|---|
| Mean | 27.5 ± 4.5 |
| Sex: Female, Male(Participants) | Diclofenac Sodium Gel 1% |
|---|---|
| Female | 37 |
| Male | 49 |
| Region of Enrollment(participants) | Diclofenac Sodium Gel 1% |
|---|---|
| United States | 86 |
The record gives a start of Oct 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diclofenac Sodium Gel